Pharma News

23ME610 by 23AndMe Holding for Metastatic Renal Cell Carcinoma: Likelihood of Approval

Photo of MEEFRO MEEFRO Send an email February 22, 2024
0 0 Less than a minute

23ME610 is under clinical development by 23andMe Holding and currently in Phase II for Metastatic Renal Cell Carcinoma.

Source link
#23ME610 #23AndMe #Holding #Metastatic #Renal #Cell #Carcinoma #Likelihood #Approval

Photo of MEEFRO MEEFRO Send an email February 22, 2024
0 0 Less than a minute
Photo of MEEFRO

MEEFRO

Related Articles

What is the current valuation of AstraZeneca’s Sabestomig

April 16, 2024

What is the current valuation of AbbVie’s ABBV-400

April 16, 2024

What is the current valuation of Merck’s MK-1084

April 16, 2024

What is the current valuation of AstraZeneca’s AZD-9574

April 16, 2024

Leave a Reply

Your email address will not be published. Required fields are marked *